The CJC-1295 ipamorelin stack is the single most commonly injected combination in the biohacker growth-hormone-peptide world. It is marketed as a safer, more "natural" alternative to recombinant human growth hormone — a way to nudge the body's own pituitary rather than replacing the hormone wholesale. The pitch is compelling. The evidence base behind it, in humans, is almost nonexistent. This article looks honestly at what each peptide is, what the stack is supposed to do, and what the peer-reviewed literature actually supports.
⚕️ Regulatory & Safety Notice
Neither CJC-1295 nor ipamorelin is FDA-approved for any indication in the United States. Both are sold as "research chemicals for laboratory use only" through gray-market peptide vendors, and both have been added to the World Anti-Doping Agency prohibited list. In 2023 the FDA moved both peptides off the 503A bulk compounding allowed category, effectively ending legal pharmacy compounding for human use. Any injectable product you can buy online is of unverified purity. Nothing in this article is medical advice. Do not self-administer unapproved peptides.
What Are CJC-1295 and Ipamorelin?
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). The parent hormone GHRH is a 44-amino-acid peptide secreted by the hypothalamus that travels to the anterior pituitary and stimulates pulsatile release of growth hormone. CJC-1295 is a modified 30-amino-acid fragment — technically a GHRH(1-29) analog — engineered with amino acid substitutions that resist degradation by dipeptidyl peptidase-4 (DPP-4), the enzyme that rapidly destroys native GHRH in plasma.
CJC-1295 exists in two forms that are almost always confused in online discussion.
- CJC-1295 without DAC (sometimes called Mod GRF 1-29) is the modified GHRH fragment alone, with a half-life of roughly 30 minutes. It produces a short, pulsatile GH release similar to the body's natural rhythm.
- CJC-1295 with DAC (drug affinity complex) adds a maleimidopropionic acid linker that covalently binds to circulating serum albumin. Albumin has a long half-life, so the bound peptide circulates for days rather than minutes. This transforms the pharmacology entirely — instead of producing a pulse of GH release, it produces a sustained elevation of baseline GH. The "with DAC" version is what the Canadian company ConjuChem originally developed as a clinical candidate before the program was discontinued.
Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) developed in the late 1990s by Novo Nordisk as a selective agonist of the growth hormone secretagogue receptor (GHSR) — the same receptor that ghrelin binds. Ipamorelin was specifically engineered to be selective: it stimulates GH release without meaningfully raising ACTH, cortisol, or prolactin, which was the chief limitation of earlier GH secretagogues like GHRP-6 and hexarelin. Novo Nordisk advanced ipamorelin into Phase 2 trials for post-operative ileus but ultimately discontinued development.
Mechanism: Why the Stack Makes Biological Sense
Growth hormone release from the pituitary is regulated by two parallel inputs. GHRH from the hypothalamus provides the primary "go" signal. Ghrelin (acting through GHSR) provides a second, amplifying signal. The two pathways converge on the same somatotroph cells but use different intracellular signaling, and their effects on GH release are synergistic, not additive — activating both receptors simultaneously produces a larger GH pulse than the sum of activating each alone.
The rationale for stacking a GHRH analog (CJC-1295) with a ghrelin mimetic (ipamorelin) is to exploit this synergy. In principle, combined administration should produce a larger, more physiologic GH pulse than either peptide alone, while preserving the selectivity of ipamorelin (no cortisol elevation) and the longer duration of CJC-1295.
This is a biologically coherent story. It is not, however, a story that has been tested in any meaningful human longevity or body composition trial.
Evidence
Here the gap between claim and data becomes uncomfortable.
CJC-1295 human data. There are essentially two published human trials of CJC-1295 with DAC from the mid-2000s ConjuChem era (Teichman et al., 2006, JCEM and follow-up pharmacokinetic work). These established that the peptide did what it was designed to do — raise circulating GH and IGF-1 levels for days after a single subcutaneous dose — and they reported generally acceptable short-term safety. They were not body composition or longevity trials. No randomized controlled trial has ever tested CJC-1295 against placebo for fat loss, lean mass gain, sleep quality, skin elasticity, or any other claim that biohacker vendors routinely make.
Ipamorelin human data. The ipamorelin clinical program targeted post-operative ileus. A Phase 2b trial (Beck et al., 2014) tested ipamorelin against placebo for accelerating return of bowel function after abdominal surgery; it failed to meet its primary endpoint and Novo Nordisk terminated development. No longevity or body composition trials exist.
The stack itself. There is no published randomized controlled trial of CJC-1295 combined with ipamorelin in humans for any indication. The entire evidence base for the stack as it is actually used consists of: (a) the synergy observed in animal studies and a handful of acute GH-release studies in healthy volunteers, (b) self-reported user data from online biohacker communities, and (c) extrapolation from the individual peptide programs that were discontinued for lack of efficacy or commercial interest. This is not a strong foundation.
Contrast with tesamorelin. It is worth noting what a properly developed GHRH analog looks like. Tesamorelin (brand name Egrifta) is a stabilized GHRH analog FDA-approved in 2010 for the treatment of HIV-associated lipodystrophy. Tesamorelin went through Phase 3 trials, demonstrated statistically significant reductions in visceral adipose tissue, and has a characterized safety profile over years of post-marketing use. It is prescribed, covered by insurance for its indication, and comes with a black-box warning about fluid retention and glucose effects. That is the evidence bar a GHRH analog can meet when it is actually developed properly. CJC-1295 has never come close.
Applications and User Claims
Common claims made for CJC-1295 + ipamorelin in the biohacker community include:
- Fat loss and improved body composition
- Lean mass preservation or gain
- Improved sleep quality, especially deep-stage sleep
- Skin and hair improvements
- Faster recovery from exercise or injury
- General "anti-aging" effects
- Improved mood and energy
Every item on this list maps to a plausible downstream effect of elevating GH and IGF-1, which the stack probably does do. Whether these effects translate into clinically meaningful, durable benefits in middle-aged adults is entirely unclear. The closest proxy is the literature on recombinant GH supplementation in healthy older adults, where the effects on body composition are real but modest, and the side-effect burden (edema, carpal tunnel, insulin resistance, joint pain) is significant enough that mainstream endocrinology has largely abandoned the use of GH as an anti-aging therapy. A 2007 meta-analysis by Liu et al. in Annals of Internal Medicine remains the most cited summary, concluding that GH in healthy elderly adults produced small lean mass increases and small fat decreases but no improvement in functional outcomes and meaningful adverse-event rates.
The biohacker pitch is that peptide secretagogues avoid these problems because they produce "natural" pulsatile GH release rather than a constant elevation. This is plausible for CJC-1295 without DAC and for ipamorelin alone, but CJC-1295 with DAC specifically produces sustained elevation rather than pulsatile release, which undermines the very argument.
Connection to Gene Editing
The growth hormone axis is one of the oldest and best-characterized longevity signaling pathways. Mice with growth hormone receptor deletions (Laron dwarf mice, studied extensively by Andrzej Bartke) live dramatically longer than wild-type counterparts. Humans with Laron syndrome — a congenital growth hormone receptor mutation — have strikingly reduced rates of cancer and diabetes despite short stature. This is precisely the opposite of what GH secretagogue stacks are trying to achieve.
Gene-editing approaches to longevity largely target down the GH/IGF-1 axis rather than stimulating it. See our explainer on the hallmarks of aging for the broader context of nutrient-sensing pathways and longevity.
This is the honest tension in the CJC-1295/ipamorelin story: the biohacker community is using peptide secretagogues to push GH/IGF-1 up, while the longevity biology literature broadly supports the idea that lower lifetime GH/IGF-1 signaling is associated with longer, healthier lifespan. Short-term body composition benefits and long-term lifespan extension may not point in the same direction.
Limitations
No long-term human safety data. Chronic elevation of GH and IGF-1 in healthy adults is associated with increased risk of insulin resistance, carpal tunnel syndrome, fluid retention, and theoretically increased cancer risk (IGF-1 is mitogenic, and epidemiological studies consistently link higher circulating IGF-1 to higher rates of several cancers). Peptide secretagogues are marketed as safer than exogenous GH; there is no long-term data to support this claim.
Unverified product purity. Gray-market peptides have been found contaminated with bacterial endotoxin, incorrect sequences, and degradation products. You cannot meaningfully evaluate your "response" to a drug when you do not know the dose or purity of what you are injecting.
Tachyphylaxis. Continuous pituitary stimulation produces receptor downregulation. The acute GH release seen on day one tends to diminish with ongoing administration, which is why most protocols include "cycling" — a practice with no empirical basis for safety or efficacy.
Legal risk. WADA bans mean athletes face sanctions. The 503A exclusion means physicians cannot legally prescribe or compound these peptides for human use in the United States.
FAQ
Is CJC-1295 + ipamorelin legal?
Neither peptide is FDA-approved. Both were removed from the 503A compounding allowed list in 2023. Possession is not criminalized federally for personal use, but sale for human use is not legal, and no legitimate pharmacy can compound either one.
Is it safer than HGH?
This is the central marketing claim and it is unsupported by data. It is biologically plausible that pulsatile stimulation is less dangerous than continuous elevation, but there are no long-term trials to confirm this.
What is the difference between CJC-1295 with and without DAC?
DAC (drug affinity complex) is a linker that binds the peptide to circulating albumin, extending half-life from about 30 minutes to several days. "With DAC" produces sustained GH elevation. "Without DAC" produces short pulses closer to natural physiology.
Why is ipamorelin preferred over GHRP-6 or hexarelin?
Ipamorelin is selective — it stimulates GH release without meaningful elevation of cortisol, ACTH, or prolactin. Earlier GH secretagogues lacked this selectivity.
How does this compare to tesamorelin?
Tesamorelin is a stabilized GHRH analog that is FDA-approved for HIV-associated lipodystrophy. It went through Phase 3 trials and has characterized safety. CJC-1295 has not. Tesamorelin is the model of what rigorous GHRH analog development looks like.
Do bodybuilders actually get results?
Self-reported user data suggests modest body composition changes. Whether these are driven by the peptide, concurrent training and diet, placebo, or confounding with other substances is impossible to determine without controlled studies. See also our review of BPC-157 evidence for a similar pattern.
